The Zhitong Finance App learned that Yaojie Ankang-B (02617) rose more than 4%. As of press release, it had risen 3.28% to HK$8.82, with a turnover of HK$23.78,800.
According to the news, Pharmacove-B announced that Gentec ® (tengotinib tablets), a new class 1 drug independently developed by the company, has been conditionally approved for marketing by the National Drug Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or inoperable cholangiocarcinoma who have received systemic treatment and FGFR inhibitors in the past and have fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement. Gentech ® is the first drug marketed and approved for this indication in China. It is expected to benefit drug-resistant patients with FGFR mutant cholangiocarcinoma and fill gaps in guidelines for the treatment of advanced biliary tract malignancies.
According to reports, on September 9, 2026, the first batch of Gentec® products completed production and successfully shipped from the factory. On September 17, 2026, the first batch of Gentec® products were officially shipped from commercial channels and sent to pharmacies across the country, officially starting commercial supply nationwide. On the same day, Gentec ® issued the country's first prescription at Peking University Cancer Hospital, marking that Gentec® has officially entered the commercial sales stage in China. Recently, Gentec ® issued the first batch of clinical prescriptions in Beijing, Shanghai, Guangdong, Jiangsu, etc., and DTP pharmacies in many parts of the country completed simultaneous distribution.